Daily Cosmetic Research Analysis
Three impactful studies span cosmetic dermatologic surgery outcomes, fluoride-free oral care, and regenerative aesthetics. A multicenter cohort shows sustained 1-year improvements in patient-reported satisfaction after Mohs surgery with location- and size-specific determinants, while a meta-analysis finds hydroxyapatite toothpaste comparable to fluoride for early caries control. A randomized split-face trial suggests ECM/SVF-gel may outperform a CO-based comparator for acne scars.
Summary
Three impactful studies span cosmetic dermatologic surgery outcomes, fluoride-free oral care, and regenerative aesthetics. A multicenter cohort shows sustained 1-year improvements in patient-reported satisfaction after Mohs surgery with location- and size-specific determinants, while a meta-analysis finds hydroxyapatite toothpaste comparable to fluoride for early caries control. A randomized split-face trial suggests ECM/SVF-gel may outperform a CO-based comparator for acne scars.
Research Themes
- Patient-reported outcomes and aesthetic satisfaction after dermatologic oncology surgery
- Fluoride-free hydroxyapatite toothpaste efficacy for early caries prevention and remineralization
- Regenerative aesthetics using ECM/SVF-gel for acne scar improvement
Selected Articles
1. Patient-reported quality of life and aesthetic satisfaction continues to improve for 1-year after Mohs surgery: A multicenter prospective cohort study.
In a 4-center prospective cohort (N=990), patient-reported aesthetic satisfaction and quality-of-life scores improved over one year after facial Mohs surgery. Tumor location (notably nose), defect size, sex, and prior history significantly influenced outcomes, whereas reconstruction type did not.
Impact: This large, multicenter, prospective dataset clarifies determinants of patient-reported outcomes after Mohs surgery, informing personalized counseling and expectation management.
Clinical Implications: Use tumor location and defect size to risk-stratify for psychosocial distress and lower scar satisfaction; counsel patients with nasal or periocular tumors accordingly. Reconstruction technique may be chosen for oncologic/functional reasons without compromising satisfaction.
Key Findings
- Patient-reported FACE-Q satisfaction improved across 1 year post-Mohs surgery.
- Nasal tumor location associated with lower appearance and scar satisfaction (P = .026, P < .001) and higher psychosocial distress (P = .004).
- Larger defects increased psychosocial distress (P = .037) and reduced scar appraisal (P = .008). Reconstruction type did not influence satisfaction.
Methodological Strengths
- Multicenter prospective cohort with large sample size (N=990)
- Use of a validated patient-reported outcome instrument (FACE-Q) with repeated measures
Limitations
- Observational design limits causal inference
- Potential selection and residual confounding; conducted in U.S. centers only
Future Directions: Integrate PROs into shared decision-making and develop targeted psychosocial interventions for high-risk sites (nose, periocular). Validate findings internationally and assess digital tools to monitor recovery.
2. The role of hydroxyapatite-based, fluoride-free toothpastes on the prevention and the remineralization of initial caries lesions: A systematic review and meta-analysis.
This systematic review and meta-analysis of in situ RCTs found hydroxyapatite toothpaste comparable to fluoride in preventing lesion development/progression by DMFS/ICDAS, with significant benefits in lesion size and fluorescence at 6 months. Pooled RR (0.98) and OR (0.90) were non-significant, supporting HAP as a fluoride-free alternative.
Impact: Addresses growing demand for fluoride-free oral care with quantitative synthesis suggesting equivalence to fluoride for early caries control.
Clinical Implications: Hydroxyapatite toothpaste can be recommended as a fluoride-free option for patients seeking non-fluoride products, particularly for early enamel lesions, with monitoring as standard of care.
Key Findings
- No significant differences between HAP and fluoride toothpastes for lesion development/progression (DMFS/ICDAS).
- Significant improvements at 6 months in lesion size (p < 0.0001) and fluorescence values (p = 0.01) favoring HAP.
- Meta-analysis: RR 0.98 (p = 0.61; 95% CI 0.85–1.12) and OR 0.90 (p = 0.68; 95% CI 0.57–1.42) showed no significant differences.
Methodological Strengths
- Comprehensive multi-database search with PRISMA-aligned methods
- Quantitative synthesis (meta-analysis) of randomized in situ trials
Limitations
- Only four eligible studies; limited power and generalizability
- In situ RCT context and short follow-up (6 months) may not fully reflect clinical conditions
Future Directions: Conduct pragmatic, longer-term clinical RCTs across age groups to confirm equivalence and evaluate caries incidence, safety, and adherence in real-world settings.
3. Comparison of the Effects of Adipose Extracellular Matrix/Stromal Vascular Fraction Gel Injection and CO
In an assessor-blinded, randomized split-face trial (11 enrolled; 10 completed), a single ECM/SVF-gel injection achieved greater 24-week ECCA scar score reductions than a CO-based comparator on the contralateral side, with an acceptable safety profile.
Impact: Provides early randomized evidence that regenerative, autologous ECM/SVF-gel may outperform a device-based comparator for acne scars, supporting regenerative aesthetics.
Clinical Implications: ECM/SVF-gel injections may be considered for moderate-to-severe acne scars as a regenerative filler option, with split-face data suggesting superior scar score reduction at 24 weeks versus a CO-based modality.
Key Findings
- Randomized, assessor-blinded split-face design comparing ECM/SVF-gel vs a CO-based comparator.
- At 24 weeks, mean ECCA score change favored ECM/SVF-gel (-60.25) over the CO side (-43.25).
- Trial registration reported (NCT06116162); safety deemed acceptable.
Methodological Strengths
- Randomized split-face within-subject comparison with assessor blinding
- Prospective design with a prespecified clinical endpoint (ECCA) and trial registration
Limitations
- Small single-center sample (10 completers) limits generalizability and power
- Open-label to participants/providers; comparator details truncated/unclear in report
Future Directions: Larger, multicenter RCTs with standardized comparators and longer follow-up should verify efficacy, optimize dosing/technique, and evaluate durability and safety.